TU
TEVA icon

TDAM USA’s Teva Pharmaceuticals TEVA Stock Holding History

TDAM USA’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,170
Closed -$260K – 423
2015
Q1 		$260K Buy
+4,170
New +$242K 0.01% 368
2013
Q3 		– Sell
-10,512
Closed -$402K – 337
2013
Q2 		$402K Buy
+10,512
New +$409K 0.02% 204

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

TDAM USA's TEVA Position: Q2 2015 in Review

TDAM USA sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 4,170 shares — an estimated $260K sold.

TDAM USA first reported a position in TEVA in Q2 2013 and held it in 2 quarters. The position peaked at $402K in Q2 2013. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • TDAM USA reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • TDAM USA sold 4,170 Teva Pharmaceuticals shares in Q2 2015, an estimated $260K.
  • TDAM USA first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • TDAM USA's Teva Pharmaceuticals position peaked at $402K in Q2 2013.
  • 818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on TDAM USA's 13F filing for Q2 2015, filed 11 Aug 2015.